Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal (CRC), pancreatic, lung and breast cancers.</li><li>The company's primary indication is first line metastatic CRC in patients with Rat Sarcoma (RAS) mutations.</li><li>Onvansertib is an oral Polo-like kinase 1 (PLK1)-selective inhibitor that has synergies with bevacizumab & various chemotherapy regimens.</li></ul>

Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal (CRC), pancreatic, lung and breast cancers.The company's primary indication is first line metastatic CRC in patients with Rat Sarcoma (RAS) mutations.Onvansertib is an oral Polo-like kinase 1 (PLK1)-selective inhibitor that has synergies with bevacizumab & various chemotherapy regimens.

<ul><li>Zacks Small-Cap Research Note for Cardiff Oncology, Inc. (CRDF)</li></ul>

Zacks Small-Cap Research Note for Cardiff Oncology, Inc. (CRDF)

<ul>
<li>Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal (CRC), pancreatic, lung and breast cancers.</li>
<li>The company's primary indication is first line metastatic CRC in patients with Rat Sarcoma (RAS) mutations.</li>
<li>Onvansertib is an oral Polo-like kinase 1 (PLK1)-selective inhibitor that has synergies with bevacizumab &amp; various chemotherapy regimens.</li>
</ul>


Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal (CRC), pancreatic, lung and breast cancers.
The company's primary indication is first line metastatic CRC in patients with Rat Sarcoma (RAS) mutations.
Onvansertib is an oral Polo-like kinase 1 (PLK1)-selective inhibitor that has synergies with bevacizumab &amp; various chemotherapy regimens.


CRDF: Initiating Coverage - Combination Therapy Elicits Superior Response

United States

Cardiff Oncology, Inc. operates as a biotech company. The Company develops therapies and treatments for solid tumor and hematologic cancers. Cardiff Oncology serves customers in the States of California.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cardiff Oncology (CRDF US)

CRDF: First Quarter 2026 Results

Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal...

Zacks Small Cap Research

CRDF: Colorectal Cancer KOL Event

Zacks Small-Cap Research Note for Cardiff Oncology, Inc. (CRDF)

Zacks Small Cap Research

CRDF: 10-K Filing Prompts Model Update

Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal...

Zacks Small Cap Research

CRDF: New CEO Presents Phase II Readout

Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal...

Zacks Small Cap Research

CRDF: Initiating Coverage - Combination Therapy Elicits Superior Response

Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)